Literature DB >> 10637404

Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil.

M Evans1, A Ellis, D Watson, T Chowdhury.   

Abstract

OBJECTIVES: To audit response to the anticholinesterase inhibitor donepezil in patients referred to a specialist memory clinic, to identify possible means of targeting the drug more accurately.
DESIGN: All referrals to the clinic who were assessed and treated against a protocol, with structured follow-up.
SUBJECTS: All referrals of any age with the diagnosis of probable Alzheimer's disease, mild to moderately severe. Main outcome measures Cognitive improvement as measured by serial ADAS-cog and MMSE examinations.
RESULTS: Two hundred and eight-two patients commenced on treatment, improved cognitive functioning in over 65% of patients reaching 3 months (N=184), 51% on intention to treat analysis (N=231), with significantly greater improvement (p=0.03) in those aged 65 and under. Carer reports of behavioural improvement not always linked to cognitive improvement. Trend to increased response in those on concomitant antidepressants.
CONCLUSION: Three-month assessment for response prior to agreeing continuation of treatment selects a group who maintain their response. Younger patients should be targeted for early assessment and treatment. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10637404     DOI: 10.1002/(sici)1099-1166(200001)15:1<50::aid-gps75>3.0.co;2-m

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  12 in total

Review 1.  Memory clinics.

Authors:  D Jolley; S M Benbow; M Grizzell
Journal:  Postgrad Med J       Date:  2006-03       Impact factor: 2.401

2.  Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease.

Authors:  P J Connelly; N P Prentice; K G Fowler
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

3.  Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635.

Authors:  C Balducci; M Nurra; A Pietropoli; R Samanin; M Carli
Journal:  Psychopharmacology (Berl)       Date:  2003-03-05       Impact factor: 4.530

4.  Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.

Authors:  Marwan Sabbagh; Jeffrey Cummings; Daniel Christensen; Rachelle Doody; Martin Farlow; Liang Liu; Joan Mackell; Randi Fain
Journal:  BMC Geriatr       Date:  2013-06-06       Impact factor: 3.921

5.  Memory clinics in context.

Authors:  David Jolley; Esme Moniz-Cook
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

6.  Predictors of long-term cognitive outcome in Alzheimer's disease.

Authors:  Carina Wattmo; Asa K Wallin; Elisabet Londos; Lennart Minthon
Journal:  Alzheimers Res Ther       Date:  2011-07-20       Impact factor: 6.982

7.  Higher levels of thyroxine may predict a favorable response to donepezil treatment in patients with Alzheimer disease: a prospective, case-control study.

Authors:  Yu San Chang; Yu Hsuan Wu; Chin Jen Wang; Shu Hui Tang; Hsiang Lan Chen
Journal:  BMC Neurosci       Date:  2018-06-22       Impact factor: 3.288

8.  Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.

Authors:  Carina Wattmo; Asa K Wallin; Lennart Minthon
Journal:  BMC Neurol       Date:  2012-11-05       Impact factor: 2.474

9.  Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.

Authors:  Carina Wattmo; Åsa K Wallin
Journal:  Alzheimers Res Ther       Date:  2017-08-31       Impact factor: 6.982

10.  Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior.

Authors:  Alexander Hawlitschka; Carsten Holzmann; Andreas Wree; Veronica Antipova
Journal:  Toxins (Basel)       Date:  2018-09-11       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.